BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25458080)

  • 1. Immunohistochemical expression of mTOR in germinal center and nongerminal center group of diffuse large B-cell lymphoma: a clinicopathological study.
    Vajpayee N; Burack R; Wang D; Hutchison RE; Gajra A
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):159-63. PubMed ID: 25458080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
    Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
    Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.
    Teoh CS; Lee SY; Chiang SK; Chew TK; Goh AS
    Asian Pac J Cancer Prev; 2018 May; 19(5):1229-1236. PubMed ID: 29801406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.
    Hernandez-Ilizaliturri FJ; Deeb G; Zinzani PL; Pileri SA; Malik F; Macon WR; Goy A; Witzig TE; Czuczman MS
    Cancer; 2011 Nov; 117(22):5058-66. PubMed ID: 21495023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity and complexes of mTOR in diffuse large B-cell lymphomas--a tissue microarray study.
    Sebestyén A; Sticz TB; Márk A; Hajdu M; Timár B; Nemes K; Nagy N; Váradi Z; Kopper L
    Mod Pathol; 2012 Dec; 25(12):1623-8. PubMed ID: 22899290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study.
    Xie Y; Bulbul MA; Ji L; Inouye CM; Groshen SG; Tulpule A; O'Malley DP; Wang E; Siddiqi IN
    Am J Clin Pathol; 2014 Apr; 141(4):593-604. PubMed ID: 24619762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of mammalian target of rapamycin in diffuse large B-cell lymphoma: a clinicopathological study.
    Vajpayee N; Thakral C; Gopaluni S; Newman N; Gajra A
    Leuk Res; 2012 Nov; 36(11):1403-9. PubMed ID: 22902049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression.
    Oh EJ; Yang WI; Cheong JW; Choi SE; Yoon SO
    Hum Pathol; 2014 Oct; 45(10):2043-50. PubMed ID: 25149548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients.
    Amen F; Horncastle D; Elderfield K; Banham AH; Bower M; Macdonald D; Kanfer E; Naresh KN
    Histopathology; 2007 Jul; 51(1):70-9. PubMed ID: 17593082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma.
    Makino K; Nakamura H; Shinojima N; Kuroda JI; Yano S; Mikami Y; Mukasa A
    J Neurooncol; 2018 Oct; 140(1):115-121. PubMed ID: 29968039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary breast diffuse large B-cell lymphoma shows a non-germinal center B-cell phenotype.
    Yoshida S; Nakamura N; Sasaki Y; Yoshida S; Yasuda M; Sagara H; Ohtake T; Takenoshita S; Abe M
    Mod Pathol; 2005 Mar; 18(3):398-405. PubMed ID: 15492762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma.
    Barrans SL; Carter I; Owen RG; Davies FE; Patmore RD; Haynes AP; Morgan GJ; Jack AS
    Blood; 2002 Feb; 99(4):1136-43. PubMed ID: 11830458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma.
    Bedekovics T; Hussain S; Feldman AL; Galardy PJ
    Blood; 2016 Mar; 127(12):1564-74. PubMed ID: 26702068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
    Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
    Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis.
    Berglund M; Thunberg U; Amini RM; Book M; Roos G; Erlanson M; Linderoth J; Dictor M; Jerkeman M; Cavallin-Ståhl E; Sundström C; Rehn-Eriksson S; Backlin C; Hagberg H; Rosenquist R; Enblad G
    Mod Pathol; 2005 Aug; 18(8):1113-20. PubMed ID: 15920553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features.
    Liu Y; Yu K; Li M; Zeng K; Wei J; Li X; Liu Y; Zhao D; Fan L; Yu Z; Wang Y; Li Z; Zhang W; Bai Q; Yan Q; Guo Y; Wang Z; Guo S
    Hum Pathol; 2017 Jun; 64():213-221. PubMed ID: 28438623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
    Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
    J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bcl-6 and c-Myc are rarely co-expressed in adult diffuse large B-cell lymphoma.
    Wagner SD; Amen F; Trivedi PS; Horncastle D; Elderfield K; Naresh KN
    Leuk Lymphoma; 2007 Aug; 48(8):1510-3. PubMed ID: 17701581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma.
    Obermann EC; Csato M; Dirnhofer S; Tzankov A
    J Clin Pathol; 2009 Oct; 62(10):903-7. PubMed ID: 19783718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Most primary central nervous system diffuse large B-cell lymphomas occurring in immunocompetent individuals belong to the nongerminal center subtype: a retrospective analysis of 31 cases.
    Hattab EM; Martin SE; Al-Khatib SM; Kupsky WJ; Vance GH; Stohler RA; Czader M; Al-Abbadi MA
    Mod Pathol; 2010 Feb; 23(2):235-43. PubMed ID: 19935644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.